Targeting microRNA-132 protects against kidney fibrosis and restricts myofibroblast differentiation from cells of

Loïs A K van der Pluijm1, Angela Koudijs1, Jacques Mgj Duijs1

  • 1Department of Internal Medicine (Nephrology) and the Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Centre, Leiden, The Netherlands.

Insights

Silencing microRNA-132 (miR-132) reduces kidney fibrosis and preserves podocyte number by inhibiting myofibroblast proliferation, including those from renin lineage cells (CoRL). This highlights miR-132 as a therapeutic target for chronic kidney disease.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Cell Biology

Background:

  • Kidney fibrosis is a key driver of chronic kidney disease (CKD) progression.
  • Cells of renin lineage (CoRL) exhibit regenerative and fibrotic potential.
  • MicroRNA-132 (miR-132) influences fibrotic signaling and renin synthesis.

Purpose of the Study:

  • To investigate the role of miR-132 and CoRL in kidney fibrosis.
  • To determine if miR-132 inhibition can ameliorate kidney injury and fibrosis.

Main Methods:

  • Utilized 5/6 nephrectomy and bilateral ischemia-reperfusion injury models in renin lineage-tracing mice.
  • Administered miR-132 antimiR or scrambled control to mice.
  • Assessed renal function, fibrosis, myofibroblast accumulation, and podocyte number.

Main Results:

  • miR-132 silencing improved renal function and reduced interstitial fibrosis and myofibroblast accumulation.
  • Podocyte number was preserved upon miR-132 silencing, indicating protection from glomerular damage.
  • CoRL were confirmed to contribute to myofibroblasts, and miR-132 inhibition reduced this contribution.

Conclusions:

  • miR-132 inhibition is a promising therapeutic strategy to reduce kidney fibrosis and preserve renal function.
  • CoRL possess both regenerative and fibrogenic plasticity.
  • Targeting miR-132 offers a novel approach to manage CKD progression.